Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 38
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Am J Med Genet A ; 191(2): 564-569, 2023 02.
Artículo en Inglés | MEDLINE | ID: mdl-36333985

RESUMEN

Mucopolysaccharidosis type I (MPS I) is an autosomal recessive disorder caused by the deficiency of α-L-iduronidase and characterized by a progressive course with multisystem involvement. Clinically, MPS I is divided into two forms: (1) severe (Hurler syndrome), which presents in infancy and is characterized by rapid progressive neurological involvement; (2) attenuated (Hurler/Scheie and Scheie syndromes), which displays a slower progression and absent to mild nervous system involvement. The specific treatment for attenuated MPS I consists of enzyme-replacement therapy with laronidase (human recombinant α-L-iduronidase, Aldurazyme). We present updated data after 18 years of laronidase treatment in two siblings affected by the attenuated form of MPS I who started therapy at 5 months and 5 years of age, respectively. Clinical and laboratory data of the siblings show that long-term enzyme replacement therapy may improve/stabilize many symptoms already present at the time of the diagnosis and reduce the disease progression. This study confirms that early diagnosis and early initiation of enzyme-replacement therapy are essential to modify positively the natural history of the attenuated form of MPS I.


Asunto(s)
Terapia de Reemplazo Enzimático , Mucopolisacaridosis I , Humanos , Estudios de Seguimiento , Iduronidasa/genética , Iduronidasa/uso terapéutico , Mucopolisacaridosis I/diagnóstico , Mucopolisacaridosis I/tratamiento farmacológico , Mucopolisacaridosis I/genética , Proteínas Recombinantes/uso terapéutico , Hermanos , Lactante , Preescolar
2.
Am J Med Genet A ; 191(7): 1948-1952, 2023 07.
Artículo en Inglés | MEDLINE | ID: mdl-37045799

RESUMEN

We describe the first case of bridge therapy in alpha-mannosidosis (AM) in an infant diagnosed at only 5 months of life who underwent enzyme replacement therapy (ERT) in the pre- and peri-transplant phases. Eight ERT infusions were administered before hematopoietic stem cell transplantation (HSCT) and continued for additional 90 days until complete engraftment. The clinical and laboratory data after 3 years post-HSCT show that the early combined intervention may reduce the disease progression and the urine and plasma content of mannosyl-oligosaccharides (OS) monitored by liquid chromatography tandem mass spectrometry (LC-MS/MS). This report highlights that early diagnosis and prompt initiation of such treatments in AM are the best chance to minimize the progression of symptoms.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas , alfa-Manosidosis , Lactante , Humanos , alfa-Manosidosis/diagnóstico , alfa-Manosidosis/terapia , Terapia de Reemplazo Enzimático/métodos , Cromatografía Liquida , Espectrometría de Masas en Tándem
3.
Anal Biochem ; 557: 34-41, 2018 09 15.
Artículo en Inglés | MEDLINE | ID: mdl-30009765

RESUMEN

Dried blood spot (DBS) technology is a cheap and easy method largely applied in newborn screening. Mucopolysaccharidoses (MPS) are characterized by the deficit of enzymes that degrade glycosaminoglycans (GAGs) characterized by progressive worsening of the conditions. For a possible early diagnosis of MPS, we developed a method of uronic acid (UA)-GAGs determination in DBS of 600 healthy newborns and from a small group of MPS subjects matched for age. Spotted blood UA-GAGs of the normal newborns are composed of 67.2% chondroitin sulfate (CS), 28.6% heparan sulfate (HS) and 4.4% hyaluronic acid with a CS/HS ratio of 2.35 and a total GAGs content of 0.43 µg/DBS. A chemical evaluation of CS and HS structure was performed by measuring their disaccharide composition, sulfation and the overall charge density. The DBS of four different MPS types presented an increase of total or single UA-GAGs content and/or modifications of the CS and HS disaccharide composition as well as chemical signature also related to the MPS enzymatic defect. The modifications of the UA-GAGs composition, parameters and structure of healthy newborns determined in DBS would be useful for a possible early diagnosis of various MPS types.


Asunto(s)
Pruebas con Sangre Seca , Glicosaminoglicanos/sangre , Glicosaminoglicanos/química , Mucopolisacaridosis/sangre , Mucopolisacaridosis/diagnóstico , Conformación de Carbohidratos , Humanos , Recién Nacido
4.
BMC Med Genet ; 17: 19, 2016 Mar 10.
Artículo en Inglés | MEDLINE | ID: mdl-26965916

RESUMEN

BACKGROUND: Mucopolysaccharidosis type I is an autosomal recessive disorder caused by deficiency of α-L-iduronidase and characterized by a progressive course with multisystem involvement. Clinically, Mucopolysaccharidosis type I is classified into two forms: severe (Hurler syndrome), which presents in infancy and is characterized by rapid progressive neurological involvement and attenuated (Hurler/Scheie and Scheie syndromes), which presents with slower progression and absent to mild nervous system involvement. The specific treatment for attenuated Mucopolysaccharidosis type I consists of enzyme-replacement therapy with laronidase (human recombinant α-L-iduronidase, Aldurazyme). We present here the clinical and laboratory results in an 12-year-old patient affected by the attenuated form of Mucopolysaccharidosis type I treated by enzyme-replacement therapy from the age of 5 months, compared with his 17 year old affected sister, who started therapy at 5 years of age. CASE PRESENTATION: Clinical evaluation of these siblings shows that initiation of therapy prior of the onset of clinically detectable disease resulted in considerable improvement in outcome in the young sibling. After 12 years of enzyme-replacement therapy, facial appearance, linear growth rate, and liver and spleen volumes were normal; moreover, the degree of joint disease, vertebral, and cardiac valvular involvement were only minimal compared with those of his sister. CONCLUSION: This study demonstrates that early diagnosis and early initiation of enzyme-replacement therapy substantially modify the natural history of the attenuated form of Mucopolysaccharidosis type I.


Asunto(s)
Terapia de Reemplazo Enzimático , Iduronidasa/genética , Mucopolisacaridosis I/genética , Mucopolisacaridosis I/terapia , Adolescente , Niño , Femenino , Estudios de Seguimiento , Glicosaminoglicanos/sangre , Glicosaminoglicanos/orina , Humanos , Iduronidasa/deficiencia , Hígado/metabolismo , Masculino , Calidad de Vida , Bazo/metabolismo
5.
Glycoconj J ; 33(2): 181-8, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26873820

RESUMEN

In this study, the content, structure and residual percentages of glycosaminoglycans (GAGs) in the feces of seven breastfed newborns after ingesting a known amount of milk were studied. A comparison was made with five newborns fed with formula milk. Characterization of GAGs from milk and feces samples was performed according to previous methodology. Compared to the ingested GAGs present in milk, residual feces GAGs of breastfed newborns were <0.4 %, contrary to formula milk fed children, where the residues were ~4 %. As a consequence, >99 % of human milk GAGs are utilized as opposed to ~96 % of formula milk. Hyaluronic acid utilization was found to be fairly similar contrary to chondroitin sulfate/dermatan sulfate and heparan sulfate, which were found to be ~10-18 times lower in formula milk fed children. Our new results further demonstrate that the elevated content of human milk GAGs passes undigested through the entire digestive system of newborns, possibly protecting the infant from infections. In the distal gastrointestinal tract, these complex macromolecules are catabolized by a cohort of bacterial enzymes and constituent monosaccharides/oligosaccharides utilized for further metabolic purposes potentially useful for bacteria metabolism or internalized by intestinal cells. Thanks to their elevated structural heterogeneity, milk GAGs are used differently depending on their distinct primary structure. Finally, a different utilization and availability was observed for human milk GAGs compared to formula milk due to their various composition and structural heterogeneity.


Asunto(s)
Lactancia Materna , Glicosaminoglicanos/metabolismo , Fórmulas Infantiles , Leche Humana/metabolismo , Femenino , Humanos , Lactante , Recién Nacido , Masculino
6.
Pediatr Res ; 79(4): 603-7, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26679156

RESUMEN

BACKGROUND: Breast-fed infants have a lower incidence of acute gastroenteritis due to the presence of several anti-infective factors in human milk. The aim of this work is to study the capacity of human milk glycosaminoglycans (GAGs) to inhibit the adhesion of some common pathogenic bacteria. METHODS: GAGs were isolated from a pool of milk samples collected from different mothers during the first month of lactation. Experiments were carried out to study the ability of GAGs to inhibit the adhesion of two intestinal micro-organisms (enteropathogenic Escherichia coli serotype 0119 and Salmonella fyris) to Caco-2 and Int-407 cell lines. RESULTS: The study showed that the GAGs had an anti-adhesive effect on the two pathogenic strains studied with different degrees of inhibition. In particular, in the presence of human milk GAGs, the adhesion of S. fyris to Caco-2 cells and to Int-407 cells of both tested strains was significantly reduced. CONCLUSION: Our results demonstrated that GAGs in human milk can be one of the important defensive factors against acute diarrheal infections in breast-fed infants.


Asunto(s)
Adhesión Bacteriana/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Glicosaminoglicanos/farmacología , Intestinos/microbiología , Leche Humana/metabolismo , Salmonella/efectos de los fármacos , Células CACO-2 , Escherichia coli/fisiología , Humanos , Técnicas In Vitro , Salmonella/fisiología
7.
J Pediatr Gastroenterol Nutr ; 60(1): 127-30, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25221936

RESUMEN

OBJECTIVES: The benefits of human milk for preterm infants are mainly the result of its nutritional characteristics and the presence of biologically active compounds. Among these compounds, glycosaminoglycans (GAGs) play an emerging leading role. When mother's milk is unavailable or in short supply, pasteurised donor milk represents an important nutritional alternative. The aim of this study was to evaluate the effect of Holder pasteurisation on the concentration of different GAGs in preterm human milk. METHODS: Milk samples collected from 9 mothers having delivered preterm were divided into 2 parts. One part of each sample was immediately frozen (-80°C), whereas the other part was pasteurised with the Holder method before being frozen at -80°C. Specific analytical procedures were applied to evaluate the amount, composition, and structure of main human milk GAGs. RESULTS: No significative differences were measured between not-treated and pasteurised samples for total GAGs content, relative percentages of chondroitin sulfate and heparan sulfate, and main parameters related to galactosaminoglycans structure, even if a slight decrease of total GAGs content of ∼18% was observed in treated samples. CONCLUSIONS: Our results indicate that the Holder pasteurisation does not significatively affect the concentration of the main human milk GAGs.


Asunto(s)
Glicosaminoglicanos/análisis , Leche Humana/química , Pasteurización , Adulto , Métodos Analíticos de la Preparación de la Muestra , Resinas de Intercambio Aniónico , Secuencia de Carbohidratos , Cromatografía Líquida de Alta Presión , Femenino , Glicosaminoglicanos/química , Calor/efectos adversos , Humanos , Italia , Lactancia , Periodo Posparto , Nacimiento Prematuro , Espectrometría de Fluorescencia
8.
Electrophoresis ; 35(6): 811-8, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24338619

RESUMEN

Human milk is a unique fluid in glycobiology due to the presence of many free structurally complex oligosaccharides emerging as important dietary factors during early life and having many biological and protective functions. Methods that allow accurate profiling of oligosaccharide mixtures in this complex biological fluid with quantification of the four known genetically determined groups are welcomed. A high-voltage CE separation and detection at 254 nm of 17 neutral and acidic human milk oligosaccharide (HMO) standard along with lactose derivatized with 2-aminoacridone, using a BGE containing 20% methanol as an organic modifier and borate, able to form on-capillary anionic borate-polyol complexes, is reported. This CE approach was able to separate both neutral HMOs and acidic HMOs, with the sialic acid residue, also in the presence of lactose in high content. This method was applied to the four secretory groups individually extracted by a rapid and simple preparative step. LODs were found ranging from ∼50 to 700 fmol. We were able to measure HMO content also in the presence of excess fluorophore, or interference from proteins, peptides, salts, and other impurities normally present in this complex biological fluid. Overall, CE equipped with a UV detector is a common analytical approach and this simple CE separation offers high resolution and sensitivity for the differentiation of human milk samples related to genetic groups and days of lactation by considering that important changes in HMO content are a reflection of the lactation day.


Asunto(s)
Aminoacridinas/química , Electroforesis Capilar/métodos , Leche Humana/química , Oligosacáridos/aislamiento & purificación , Femenino , Humanos , Lactosa/química , Lactosa/aislamiento & purificación , Oligosacáridos/análisis , Oligosacáridos/química
9.
Glycoconj J ; 30(7): 727-32, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23512580

RESUMEN

Enzyme replacement therapy (ERT) is the worldwide standard of care for a number of mucopolysaccharidosis (MPS) diseases. We report a kinetic study of plasmatic dermatan sulfate (DS) in a 3-year-old subject affected by a severe form of MPS II during the first 10 months of ERT with Idursulfase. A strong increase in the DS plasmatic concentration was measured immediately after the first enzyme infusion, with a maximum after 3 h, followed by a continuous decrease in the 8-15 days following the beginning of treatment. After this, a constant plasmatic content of DS concentration was observed. Overall, during the 10-month treatment period, ERT reduced the plasmatic concentration of DS up to ~80-85 %, but it was unable to totally remove it from the blood. We can suppose that immediately after the first enzyme administrations, a large amount of abnormal DS is removed from tissues reaching the blood compartment and eliminated via the urine, and thereafter only minimal changes are observed. The persistency of the residual amounts of DS with the actually recommended dosage in our Patient may suggest the opportunity to promote further studies with increased enzyme dosages to completely remove the accumulation of lysosomal DS.


Asunto(s)
Dermatán Sulfato/sangre , Terapia de Reemplazo Enzimático , Glicoproteínas/uso terapéutico , Mucopolisacaridosis II/sangre , Adolescente , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Mucopolisacaridosis II/terapia , Adulto Joven
10.
Anal Biochem ; 430(1): 97-104, 2012 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-22885238

RESUMEN

A high-resolution normal-phase high-performance liquid chromatography-fluorescence detection-electrospray ionization-mass spectrometry separation and structural characterization of the main oligosaccharides along with lactose from human milk samples is described. A total of 22 commercially available oligosaccharides were fluorotagged with 2-aminoacridone and separated on an amide column and identified on the basis of their retention times and mass spectra. Derivatized species having mass lower than approximately 800 to 900 exhibited mainly [M-H](-1) anions, oligomers with mass up to approximately 1000 to 1100 were represented by both [M-H](-1) and [M-2H](-2) anions, and oligomers greater than approximately 1200 to 1300 were characterized by a charge state of -3. Furthermore, the retention times were directly related to the glycans' molecular mass. Human milk samples from the four groups of donors (Se±/Le±) were analyzed for their composition and amount of free oligosaccharides after rapid and simple prepurification and derivatization steps also in the presence of lactose in high content. This analytical approach enabled us to perform the determination of species not detected by traditional techniques, such as sialic acid, as well as of species present in low content easily mistaken with other peaks. Finally, labeled human milk oligosaccharides were analyzed without any interference from excess fluorophore or interference from proteins, peptides, salts, and other impurities normally present in this complex biological fluid.


Asunto(s)
Aminoacridinas/química , Cromatografía Líquida de Alta Presión/métodos , Leche Humana/química , Oligosacáridos/análisis , Oligosacáridos/química , Espectrometría de Fluorescencia/métodos , Espectrometría de Masa por Ionización de Electrospray/métodos , Secuencia de Carbohidratos , Cromatografía por Intercambio Iónico , Humanos , Datos de Secuencia Molecular , Oligosacáridos/aislamiento & purificación , Sistemas en Línea
11.
Orphanet J Rare Dis ; 17(1): 251, 2022 06 29.
Artículo en Inglés | MEDLINE | ID: mdl-35768874

RESUMEN

BACKGROUND: Mucopolysaccharidoses (MPSs) are a group of lysosomal storage disorders caused by the deficit of lysosomal hydrolases involved in the degradation of glycosaminoglycans (GAGs). The course is chronic and progressive, with multisystemic involvement that often leads to cardiovascular disease. We describe the overall incidence and type of cardiac damage in a cohort of Italian MPS patients, and their progression over time, also with reference to treatment efficacy in patients under Enzyme Replacement Therapy (ERT). Moreover, we report a possible association between genetic variants and cardiac phenotype in homozygous and hemizygous patients to understand whether a more aggressive clinical phenotype would predict a greater cardiac damage. RESULTS: Our findings confirm that cardiac involvement is very common, already at diagnosis, in MPS VI (85.7% of our cohort), and in MPS II (68% of our cohort) followed by MPS I subjects (55% of our cohort). The most frequent heart defect observed in each MPS and at any time-point of evaluation was mitral insufficiency; 37% of our patients had mitral insufficiency already at diagnosis, and 60% at post-ERT follow-up. After at least six years of treatment, we observed in some cases (including 6 MPS II, 2 MPS IV and 2 MPS VI) a total regression or improvement of some signs of the cardiac pathology, including some valve defects, though excluding aortic insufficiency, the only valvulopathy for which no regression was found despite ERT. The general clinical phenotype proved not to be strictly correlated with the cardiac one, in fact in some cases patients with an attenuated phenotype developed more severe heart damage than patients with severe phenotype. CONCLUSIONS: In conclusion, our analysis confirms the wide presence of cardiopathies, at different extent, in the MPS population. Since cardiac pathology is the main cause of death in many MPS subtypes, it is necessary to raise awareness among cardiologists about early cardiac morpho-structural abnormalities. The encouraging data regarding the long-term effects of ERT, also on heart damage, underlines the importance of an early diagnosis and timely start of ERT.


Asunto(s)
Lesiones Cardíacas , Insuficiencia de la Válvula Mitral , Mucopolisacaridosis , Mucopolisacaridosis II , Mucopolisacaridosis VI , Terapia de Reemplazo Enzimático , Lesiones Cardíacas/tratamiento farmacológico , Humanos , Incidencia , Insuficiencia de la Válvula Mitral/tratamiento farmacológico , Mucopolisacaridosis/tratamiento farmacológico , Mucopolisacaridosis II/tratamiento farmacológico , Mucopolisacaridosis VI/tratamiento farmacológico
12.
Glycobiology ; 21(3): 295-303, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21030540

RESUMEN

To date, there is no complete structural characterization of human milk glycosaminoglycans (GAGs) available nor do any data exist on their composition in bovine milk. Total GAGs were determined on extracts from human and bovine milk. Samples were subjected to digestion with specific enzymes, treated with nitrous acid, and analyzed by agarose-gel electrophoresis and high-performance liquid chromatography for their structural characterization. Quantitative analyses yielded ∼7 times more GAGs in human milk than in bovine milk. In particular, galactosaminoglycans, chondroitin sulfate (CS) and dermatan sulfate (DS), were found to differ considerably from one type of milk to the other. In fact, hardly any DS was observed in human milk, but a low-sulfated CS having a very low charge density of 0.36 was found. On the contrary, bovine milk galactosaminoglycans were demonstrated to be composed of ∼66% DS and 34% CS for a total charge density of 0.94. Structural analysis performed by heparinases showed a prevalence of fast-moving heparin over heparan sulfate, accounting for ∼30-40% of total GAGs in both milk samples and showing lower sulfation in human (2.03) compared with bovine (2.28). Hyaluronic acid was found in minor amounts. This study offers the first full characterization of the GAGs in human milk, providing useful data to gain a better understanding of their physiological role, as well as of their fundamental contribution to the health of the newborn.


Asunto(s)
Glicosaminoglicanos/química , Leche/química , Animales , Bovinos , Sulfatos de Condroitina/química , Dermatán Sulfato/química , Femenino , Heparina/química , Heparitina Sulfato/química , Humanos , Leche Humana/química
13.
Anal Biochem ; 411(1): 32-42, 2011 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-21156153

RESUMEN

Mucopolysaccharidoses (MPS) diagnosis is often delayed and irreversible organ damage can occur, making possible therapies less effective. This highlights the importance of early and accurate diagnosis. A high-throughput procedure for the simultaneous determination of glucosamine and galactosamine produced from urinary galactosaminoglycans and glucosaminoglycans by capillary electrophoresis (CE) and HPLC has been performed and validated in subjects affected by various MPS including their mild and severe forms, Hurler and Hurler-Scheie, Hunter, Sanfilippo, Morquio, and Maroteaux-Lamy. Contrary to other analytical approaches, the present single analytical procedure, which is able to measure total abnormal amounts of urinary GAGs, high molecular mass, and related fragments, as well as specific hexosamines belonging to a group of GAGs, would be useful for possible application in their early diagnosis. After a rapid urine pretreatment, free hexosamines are generated by acidic hydrolysis, derivatized with 2-aminobenzoic acid and separated by CE/UV in ∼10min and reverse-phase (RP)-HPLC in fluorescence in ∼21min. The total content of hexosamines was found to be indicative of abnormal urinary excretion of GAGs in patients compared to the controls, and the galactosamine/glucosamine ratio was observed to be related to specific MPS syndromes in regard to both their mild and severe forms. As a consequence, important correlations between analytical response and clinical diagnosis and the severity of the disorders were observed. Furthermore, we can assume that the severity of the syndrome may be ascribed to the quantity of total GAGs, as high-molecular-mass polymers and fragments, accumulated in cells and directly excreted in the urine. Finally, due to the high-throughput nature of this approach and to the equipment commonly available in laboratories, this method is suitable for newborn screening in preventive public health programs for early detection of MPS disorders, diagnosis, and their treatment.


Asunto(s)
Hexosaminas/orina , Ensayos Analíticos de Alto Rendimiento/métodos , Mucopolisacaridosis/diagnóstico , Mucopolisacaridosis/orina , Adolescente , Niño , Preescolar , Cromatografía Líquida de Alta Presión , Electroforesis Capilar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Mucopolisacaridosis/clasificación , Estándares de Referencia , Reproducibilidad de los Resultados , Temperatura , Factores de Tiempo , Rayos Ultravioleta
14.
J Pediatr Gastroenterol Nutr ; 53(1): 80-7, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21478759

RESUMEN

OBJECTIVES: The aim of this study was to identify a link between the total amount of breast milk oligosaccharides and faecal microbiota composition of newborns at the end of the first month of life, with special attention paid to bifidobacteria, and establish the role, if any, of the different oligosaccharides in determining the gut microbiota composition. SUBJECTS AND METHODS: Milk oligosaccharide groups were identified by high-performance anion exchange chromatography analysis. DPCRNA from newborns' faecal samples at 30 days of life was isolated and processed by polymerase chain reaction analyses that allow the identification of 6 species of bifidobacteria (adolescentis, bifidum, breve, catenulatum, longum, infantis) and Ruminococcus spp; denaturing gradient gel electrophoresis analysis was also performed. RESULTS: No substantial differences in bifidobacteria species composition within milk groups 1, 2, and 3 were observed; however, infants fed with group 4 milk show a microbiota characterised by a greater frequency of Bifidobacteria adolescentis and the absence of Bifidobacteria catenulatum. For the first time, a high percentage of the Ruminococcus genus in infants fed with all milk groups was found. CONCLUSIONS: Our data show that milk groups 1, 2, and 3, containing an amount of oligosaccharides ranging within 10 to 15 g/L, share a substantially identical composition of the intestinal microbiota in breast-fed infants, despite quali-quantitative difference in oligosaccharides content. Newborns taking milk with only 5 g/L of oligosaccharides (group 4) harbour a different intestinal microbiota.


Asunto(s)
Bifidobacterium/metabolismo , Lactancia Materna , Heces/microbiología , Leche Humana/metabolismo , Oligosacáridos/metabolismo , Polisacáridos Bacterianos/metabolismo , Ruminococcus/metabolismo , Adulto , Resinas de Intercambio Aniónico , Bifidobacterium/clasificación , Bifidobacterium/aislamiento & purificación , Cromatografía Líquida de Alta Presión , ADN Bacteriano/aislamiento & purificación , ADN Bacteriano/metabolismo , Electroforesis en Gel de Gradiente Desnaturalizante , Humanos , Recién Nacido , Italia , Antígenos del Grupo Sanguíneo de Lewis/metabolismo , Masculino , Tipificación Molecular , Oligosacáridos/química , Proyectos Piloto , Reacción en Cadena de la Polimerasa , Polisacáridos Bacterianos/química , Ruminococcus/clasificación , Ruminococcus/aislamiento & purificación
15.
Glycobiology ; 20(10): 1259-73, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20538645

RESUMEN

Enzyme-replacement therapy (ERT) is a new option for the clinical management of MPS I. However, no detailed data are available on the structural characterization of glycosaminoglycans (GAGs) in the urine and plasma of patients before ERT and during treatment regimens. Before ERT and over a two-week period of enzyme infusion, GAGs in urine and plasma were analyzed in two patients with the Hurler-Scheie form of MPS I subjected to ERT for 6 years. In both patients before ERT, high amounts of a GAG were found in the urine, composed in particular of a high molecular mass polymer (approximately 13,000-13,500) consisting of approximately 75-78% iduronic acid and rich in 4-sulfated disaccharides (DeltaDi4s) and attributable to DS. Furthermore, a high amount of this GAG was directly detected in the blood. Plasma GAGs in MPS I patients subjected to ERT were found to be comparable to those of normal subjects with the absence of heparan sulfate and of DS. On the contrary, a polysaccharide possessing a high molecular mass, approximately 11,500-12,000, lower than the polymer extracted before ERT but slightly higher than the controls (approximately 11,000), was found in the urine of both patients. This macromolecule was characterized as a mixture of DS/chondroitin sulfate based on the high percentage of 4-sulfated disaccharide (4s/6s ratio of approximately 3.1) and iduronic acid ( approximately 60%). These results are indicative of the incapacity of ERT at the standard dose to definitively eliminate DS from the urine. Finally, a variable effect of ERT depending on each administration was also observed.


Asunto(s)
Biomarcadores/sangre , Biomarcadores/orina , Terapia de Reemplazo Enzimático , Glicosaminoglicanos/sangre , Glicosaminoglicanos/orina , Mucopolisacaridosis I/sangre , Mucopolisacaridosis I/orina , Estudios de Casos y Controles , Disacáridos/orina , Humanos , Mucopolisacaridosis I/terapia
17.
J Matern Fetal Neonatal Med ; 33(12): 2131-2133, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-30348026

RESUMEN

Objective: In this pilot study, we report the composition, structure and properties of glycosaminoglycans (GAG) present in milk samples of various countries and ethnicities.Methods: Fifty samples of human milk were analyzed, 10 from east Europe, 10 from North Africa, 10 from Central Africa, 10 from South America and 10 from Asia. Moreover, 30 samples were obtained during the first week and 20 between 8 to 30 days of life.Results: Overall, no significant differences were observed for the qualitative composition of GAGs, mainly chondroitin sulfate, heparan sulfate and hyaluronic acid, comparing the mothers from the various countries and between the 30 milks obtained during the first week and the 20 samples collected thereafter. Moreover, no significant differences in human milk GAGs within the different groups analyzed belonging to various counties and ethnicities were observed.Conclusions: These results may be of useful, as in the case of pilot studies with infant formulas enriched with chondroitin sulfate (CS) and/or heparan sulfate (HS) necessary to verify their possible positive effects on newborns feeding in countries at high risk of infection and/or infestation.


Asunto(s)
Glicosaminoglicanos/análisis , Leche Humana/química , Humanos , Internacionalidad , Proyectos Piloto
18.
JIMD Rep ; 55(1): 15-21, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32905047

RESUMEN

Alpha mannosidosis is an ultrarare pathology with variable phenotypic manifestations, characterized by the deficiency of lysosomal alpha mannosidase which causes accumulation of neutral oligosaccharides. Until recently, the hematopoietic stem cell transplantation was the only clinical feasible therapeutic option. Only in 2018, the European Medicines Agency's committee approved the recombinant enzyme velmanase alfa for long-term treatment of non-neurological manifestations in mild and moderate forms of alpha-mannosidosis. In this study, the very early biochemical effects of enzyme replacement therapy in in a 7-month-old patient with alpha-mannosidosis were described. Velmanase alpha was administered as supporting therapy awaiting for hematopoietic stem cell transplantation, the treatment chosen for the patient because of the early onset form. The results showed that the enzyme replacement therapy was able to reduce the content of three different mannosyl-oligosaccharides monitored by tandem mass spectrometry after 2 months of treatment. In particular, the mean relative changes from baseline values were -67% in urine and -53% in serum at the latest observation. The study also showed that the enzymatic activity detected in serum 1 week after the first infusion was four times higher than the normal values and constant in the following points of observation. These findings led us to assume that velmanase alfa might be biologically active in this young patient.

19.
Mol Genet Genomic Med ; 8(10): e1371, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32779865

RESUMEN

BACKGROUND: In GM1 gangliosidosis the lack of function of ß-galactosidase results in an accumulation of GM1 ganglioside and related glycoconjugates in visceral organs, and particularly in the central nervous system, leading to severe disability and premature death. In the type 2 form of the disease, early intervention would be important to avoid precocious complications. To date, there are no effective therapeutic options in preventing progressive neurological deterioration. Substrate reduction therapy with Miglustat, a N-alkylated sugar that inhibits the enzyme glucosylceramide synthase, has been proposed for the treatment of several lysosomal storage disorders such as Gaucher type 1 and Niemann Pick Type C diseases. However, data on Miglustat therapy in patients with GM1 gangliosidosis are still scarce. METHODS: We report here the results of Miglustat administration in four Italian children (average age: 55 months, range 20-125) affected by GM1 gangliosidosis type 2 treated in three different Italian pediatric hospitals specialized in metabolic diseases. CONCLUSION: This treatment was safe and relatively well tolerated by all patients, with stabilization and/or slowing down of the neurological progression in three subjects.


Asunto(s)
1-Desoxinojirimicina/análogos & derivados , Gangliosidosis GM1/tratamiento farmacológico , Inhibidores de Glicósido Hidrolasas/uso terapéutico , 1-Desoxinojirimicina/efectos adversos , 1-Desoxinojirimicina/farmacología , 1-Desoxinojirimicina/uso terapéutico , Adolescente , Sistema Nervioso Central/diagnóstico por imagen , Sistema Nervioso Central/efectos de los fármacos , Niño , Preescolar , Tolerancia a Medicamentos , Femenino , Glucosiltransferasas/antagonistas & inhibidores , Glucosiltransferasas/metabolismo , Inhibidores de Glicósido Hidrolasas/efectos adversos , Inhibidores de Glicósido Hidrolasas/farmacología , Humanos , Lactante , Masculino
20.
J Matern Fetal Neonatal Med ; 32(17): 2950-2952, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-29562795

RESUMEN

Background: It is well known that human milk oligosaccharides play an important role as prebiotics, anti-inflammatory, and anti-infective agents. In the last few years, several studies have been performed using specific oligosaccharides, such as 2'-fucosyllactose and 6'-sialylactose, to evaluate their biological functions. Objectives: The aim of the present study is to evaluate the anti-adhesive effect of the above oligosaccharides on Escherichia coli and Salmonella fyris. Methods: Adhesion experiments were performed in the presence of 2'-fucosyllactose and 6'-sialyllactose as potential inhibitors of Escherichia coli and Salmonella fyris adhesion to Caco-2 cells. The oligosaccharides were used at different concentrations and the adhesion experiments were performed in triplicate and repeated at least three times. Results: A significant reduction of Escherichia coli adhesion was observed in the presence of 2'-fucosyllactose and 6'-sialyllactose at the human milk concentration. On the contrary, no positive effects were observed in both oligosaccharides on Salmonella firis. Conclusions: Our results suggest that the supplementation in infant formulas of 2'-fucosyllactose and 6'-sialyllactose, actually commercially available and absent in cow milk, could play positive effects in artificially fed infants.


Asunto(s)
Adhesión Bacteriana/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Lactosa/análogos & derivados , Leche Humana/química , Trisacáridos/farmacología , Suplementos Dietéticos , Humanos , Fórmulas Infantiles , Recién Nacido , Lactosa/farmacología , Salmonella/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA